Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) kicked off on Monday, up 7.12% from the previous trading day, before settling in for the closing price of $22.33. Over the past 52 weeks, ARWR has traded in a range of $20.67-$42.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 205.96% over the last five years. While this was happening, its average annual earnings per share was recorded -37.79%. With a float of $117.63 million, this company’s outstanding shares have now reached $123.90 million.
The firm has a total of 525 workers. Let’s measure their productivity.
Arrowhead Pharmaceuticals Inc. (ARWR) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Arrowhead Pharmaceuticals Inc. is 5.06%, while institutional ownership is 64.26%. The most recent insider transaction that took place on Apr 01 ’24, was worth 168,180. In this transaction Chief Discovery/Trans Medicine of this company sold 6,000 shares at a rate of $28.03, taking the stock ownership to the 204,851 shares. Before that another transaction happened on Mar 20 ’24, when Company’s Director bought 1,000 for $27.50, making the entire transaction worth $27,500. This insider now owns 33,680 shares in total.
Arrowhead Pharmaceuticals Inc. (ARWR) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -37.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.33% during the next five years compared to -24.19% drop over the previous five years of trading.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Trading Performance Indicators
Take a look at Arrowhead Pharmaceuticals Inc.’s (ARWR) current performance indicators. Last quarter, stock had a quick ratio of 3.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.77, a number that is poised to hit -0.47 in the next quarter and is forecasted to reach -2.50 in one year’s time.
Technical Analysis of Arrowhead Pharmaceuticals Inc. (ARWR)
Analysing the last 5-days average volume posted by the [Arrowhead Pharmaceuticals Inc., ARWR], we can find that recorded value of 1.06 million was lower than the volume posted last year of 1.48 million. As of the previous 9 days, the stock’s Stochastic %D was 26.93%. Additionally, its Average True Range was 1.32.
During the past 100 days, Arrowhead Pharmaceuticals Inc.’s (ARWR) raw stochastic average was set at 16.96%, which indicates a significant decrease from 41.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.20% in the past 14 days, which was lower than the 82.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $28.66, while its 200-day Moving Average is $29.25. Now, the first resistance to watch is $24.73. This is followed by the second major resistance level at $25.55. The third major resistance level sits at $26.80. If the price goes on to break the first support level at $22.67, it is likely to go to the next support level at $21.42. Now, if the price goes above the second support level, the third support stands at $20.61.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Key Stats
The company with the Market Capitalisation of 2.96 billion has total of 123,897K Shares Outstanding. Its annual sales at the moment are 240,740 K in contrast with the sum of -205,280 K annual income. Company’s last quarter sales were recorded 3,550 K and last quarter income was -132,860 K.
